|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance显示文摘The Hepatitis B Virus(HBV) has a worldwide distribu-tion and is endemic in many populations. It is constantly evolving and 10 genotypic strains have been identified with varying prevalences in different geographic regions. Numerous stable mutations in the core gene and in the su-rface gene of the HBV have also been identified in untreated HBV populations. The genotypes and viral variants have been associated with certain clinical featu-res of HBV related liver disease and Hepatocellu-lar carcinoma. For example Genotype C is associated withlater hepatitis B e antigen(HBe Ag) seroconversion, and more advanced liver disease. Genotype A is associated with a greater risk of progression to chronicity in adu-lt acqu-ired HBV infections. Genotype D is particu-larly associated with the precore mu-tation and HBe Ag negative chronic hepatitis B(CHB). The genotypes prevalent in parts of West Africa, Central and Sou-th America, E, F and H respectively, are less well stu-died. Viral variants especially the Basal Core Promotor mutation is associated with increased risk of fibrosis and cancer of the liver. Althou-gh not cu-rrently part of rou-tine clinical care, evalu-ation of genotype and viral variants may provide u-sefu-l adju-nctive information in predicting risk abou-t liver related morbidity in patients with CHB. | Catherine MN Croagh Paul V Desmond Sally J Bell | 2015 | World Journal of Hepatology2015，7，3： | 24 |
| 2 | Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience显示文摘AIM To evaluate the long-term treatment outcomes of tenofovir therapy in patients in a real world Australian tertiary care setting.METHODS We performed a retrospective analysis of treatment outcomes among treatment-na?ve and treatment-experienced patients receiving a minimum 3 mo tenofovir therapy through St Vincent's Hospital Melbourne, Australia. We included patients receiving tenofovir [tenofovir disoproxil fumarate(TDF)] monotherapy, as well as patients treated with TDF in combination with a second antiviral agent. Patients were excluded if they demonstrated human immune-deficiency virus/hepatitis C virus/hepatitis delta virus coinfection or were less than 18 years of age. We considered virological and biochemicalresponse, as well as safety outcomes. Virological response was determined by measurement of hepatitis B virus(HBV) DNA using sensitive assays; biochemical response was determined via serum liver function tests; histological response was determined from liver biopsy and fibroscan; safety analysis focused on glomerular renal function and bone mineral density. The primary efficacy endpoint was complete virological suppression over time, defined by HBV DNA < 20 IU/m L. Secondary efficacy endpoints included rates of biochemical response, and HB e antigen(HBe Ag)/HB surface antigen loss and seroconversion over time.RESULTS Ninety-two patients were identified who fulfilled the enrolment criteria. Median follow-up was 26 mo(range 3-114). Mean age was 46(24-78) years, 64(70%) were male and 77(84%) were of Asian origin. 55(60%) patients were treatment-na?ve and 62 patients(67%) were HBe Ag-negative. Complete virological suppression was achieved by 45/65(71%) patients at 12 mo, 37/46(80%) at 24 mo and 25/28(89%) at 36 mo. Partial virological response(HBV DNA 20-2000 IU/m L) was achieved by 89/92(96.7%) of patients. Multivariate analysis showed a significant relationship between virological suppression at end of follow-up and baseline HBV DNA level(OR = 0.897, 95%CI: 0.833-0.967, P = 0.0046) and HBe Ag positive status(OR = 0.373, 95%CI: 0.183-0.762, P = 0.0069). There was no difference in response comparing treatment-na?ve and treatment-experienced patients. Three episodes of virological breakthrough occurred in the setting of noncompliance. Tenofovir therapy was well tolerated.CONCLUSION Tenofovir is an efficacious, safe and well-tolerated treatment in an Australian real-world tertiary care setting. Our data are similar to the reported experience from registration trials. | Grace C Lovett Tin Nguyen David M Iser Jacinta A Holmes Robert Chen Barbara Demediuk Gideon Shaw Sally J Bell Paul V Desmond Alexander J Thompson | 2017 | World Journal of Hepatology2017，9，1： | 7 |
| 3 | Infectious hypodermal and hematopoietic necrosis, a newly recognized virus disease of penaeid shrimp显示文摘 | Lightner D V Redman R M Bell T A | 1983 | Invertebrate Pathology1983，42，： | 2 |
| 4 | IL 28 B genotype is not useful for predicting treatment outcome in A sian chronic hepatitis B patients treated with pegylated interferon‐α显示文摘 | Jacinta A Holmes Tin Nguyen Dilip Ratnam Neel M Heerasing Jane V Tehan Sara Bonanzinga Anouk Dev Sally Bell Stephen Pianko Robert Chen Kumar Visvanathan Rachel Hammond David Iser Ferry Rusli William Sievert Paul V Desmond D Scott Bowden Alexander J Thomps | 2013 | J Gastroenterol Hepatol2013，，5： | 2 |
| 5 | Effect β-glucan from oat and yeast on serum lipids显示文摘 | Bell S Coldmanm V M Bistrian B R | 1999 | Critical reviews in food science and nutrition1999，39，： | 1 |
| 6 | Randomised,phase Ⅱ trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines显示文摘 | Talbot DC Moiseyenko V van Belle S | 2002 | Br J Cancer2002，86，： | 1 |
| 7 | Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rats显示文摘 | Parmar R Bell CJ Dalal V | 1996 | Gut1996，38，4： | 1 |
| 8 | Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternative spliced exons显示文摘 | Screaton G R Bell M V Jackson D G | 1992 | Proc Natl Acad Sci USA1992，89，12： | 1 |
| 9 | Price Competition under Stockpiling and Flexible Con- sumption显示文摘 | BELL D R IYER G PADMANABHAN V | 2002 | Journal of Marketing Research2002，39，8： | 1 |
| 10 | Epigenetie inactivation of14-3-3 sigma in oral carcinoma : association with p16 (INK4a) silencing and human papillomavirus negativity 显示文摘 | Gasco M Bell AK Heath V | 2002 | Cancer Res2002，62，： | 1 |
| 11 | Natural and recombinant fungal laccases for paper pulp bleaching显示文摘 | S1GOILLOT C RECORD E BELLE V | 2004 | Applied Microbiology&Biotechnology2004，64，3： | 1 |
| 12 | Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis显示文摘 | Van Belle V Van Calster B Brouckaert O | 2010 | J Clin Oncol2010，28，27： | 1 |
| 13 | P38-dependent enhancement of cytokine-induced nitric-oxide synthase gene expression by heat shock protein 70显示文摘 | Bell mann K Burkart V Bruckhoff J | 2000 | J Boil Chem2000，275，18： | 1 |
| 14 | Requirement criteria for essential fatty acid 显示文摘 | Sargent J R Bell J G Bell M V | 1995 | J Appl Iehthyol1995，11，： | 1 |
| 15 | Online information, extreme communities and intemet therapy:is the intemet good for our mental health? 显示文摘 | Bell V | 2007 | J Ment Health2007，16，4： | 1 |
| 16 | Infectious hypodermal and hematopoietic necrosis, a newly recognized virus disease of penaeid shrimp显示文摘 | Lightner D V Redman R M Bell T A | 1983 | Invertebrate Pathology1983，42，： | 1 |
| 17 | Gasdynamic model of turbulent combustion in TNT explosions显示文摘 | Kuhl AL Bell J B Beckner V E | 2011 | Proceedings of the Combustion Institute2011，33，2： | 1 |
| 18 | Infectious hypodermal and haematopoietic necrosis, a newly recognized virus disease of penaeid shrimp 显示文摘 | Lighter D V Redman R M Bell T A | 1983 | J Invertebr Pathol1983，42，： | 1 |
| 19 | Epidermal growth factor receptor mutations in lung cancer显示文摘 | Sharma S V Bell D W Settleman J | 2007 | Nat Rev Cancer2007，7，3： | 1 |
| 20 | Plasma formation and implosion structure in wire array Z pinches显示文摘 | Chittenden J P LebedevS V Bell A R | 1999 | PhysRev Lett1999，83，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员